Under construction – not a live service
Sign in
Taking people in CzechiaPhase 1

Bimekizumab given by vein or by injection in psoriatic arthritis and axial spondyloarthritis

Compares bimekizumab given by vein or injection in adults with active joint disease.

Plain-language title generated from the registry record
Registry title: A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Key facts

Where
Brno, Hlučín, Ostrava, and Uherské Hradiště, CzechiaSee the 4 sites
Phase
Phase 1

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active psoriatic arthritis or active axial spondyloarthritis who can have bimekizumab treatment. It compares bimekizumab given into a vein with bimekizumab given as an injection under the skin.

Age
18 years or older, and able to give legal consent.
Sex
All sexes can join.
Disease stage
Active psoriatic arthritis (PsA) or active axial spondyloarthritis (axSpA).
Earlier treatment
People must have had no biologic disease-modifying anti-rheumatic drug (bDMARD) before, or must have stopped it at least 3 months or 5 half-lives ago.

Main reasons for not taking part

  • Serious organ disorders (for example heart, liver, kidney, gut or nervous system)
  • Severe psychiatric problems or substance abuse in the past year
  • Recent or long-lasting infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB)
  • Other inflammatory diseases (for example rheumatoid arthritis, lupus, inflammatory bowel disease)
  • Recent live vaccine (within 8 weeks), BCG vaccine (within 1 year) or GLP-1 agonist use (within 28 weeks)

Read by machine on 9 November 2026.

Where in Czechia

  • Pa0019 705Brno, CzechiaTaking people
  • Pa0019 703Hlučín, CzechiaTaking people
  • Pa0019 704Ostrava, CzechiaTaking people
  • Pa0019 702Uherské Hradiště, CzechiaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
UCB Biopharma SRL
Trial code
NCT07290036
Record updated
6 November 2026
Original description
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.Read full original descriptionShow less

An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

Inclusion: Be 18+ years old and legally able to consent; Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment; Weigh between 45-100 kg (females) or 50-100 kg (males); Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago.

Exclusion: Recent live vaccines (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year); Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro); Severe psychiatric issues or substance abuse in the past year; Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB); Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD)); Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks).

ClinicalTrials.gov NCT07290036